Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth
- PMID: 25763405
- PMCID: PMC4334071
- DOI: 10.1155/2014/719050
Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth
Abstract
Polycystic ovary syndrome (PCOS) is a highly prevalent endocrine-metabolic disorder that implies various severe consequences to female health, including alarming rates of infertility. Although its exact etiology remains elusive, it is known to feature several hormonal disturbances, including hyperandrogenemia, insulin resistance (IR), and hyperinsulinemia. Insulin appears to disrupt all components of the hypothalamus-hypophysis-ovary axis, and ovarian tissue insulin resistance results in impaired metabolic signaling but intact mitogenic and steroidogenic activity, favoring hyperandrogenemia, which appears to be the main culprit of the clinical picture in PCOS. In turn, androgens may lead back to IR by increasing levels of free fatty acids and modifying muscle tissue composition and functionality, perpetuating this IR-hyperinsulinemia-hyperandrogenemia cycle. Nonobese women with PCOS showcase several differential features, with unique biochemical and hormonal profiles. Nevertheless, lean and obese patients have chronic inflammation mediating the long term cardiometabolic complications and comorbidities observed in women with PCOS, including dyslipidemia, metabolic syndrome, type 2 diabetes mellitus, and cardiovascular disease. Given these severe implications, it is important to thoroughly understand the pathophysiologic interconnections underlying PCOS, in order to provide superior therapeutic strategies and warrant improved quality of life to women with this syndrome.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4334071/bin/IJRMED2014-719050.001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4334071/bin/IJRMED2014-719050.002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4334071/bin/IJRMED2014-719050.003.gif)
Similar articles
-
Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.J Obstet Gynaecol. 2019 Oct;39(7):975-980. doi: 10.1080/01443615.2019.1581754. Epub 2019 May 7. J Obstet Gynaecol. 2019. PMID: 31064233
-
Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.J Clin Endocrinol Metab. 1997 Oct;82(10):3389-94. doi: 10.1210/jcem.82.10.4318. J Clin Endocrinol Metab. 1997. PMID: 9329374
-
Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia.Fertil Steril. 1994 Apr;61(4):605-12. doi: 10.1016/s0015-0282(16)56633-3. Fertil Steril. 1994. PMID: 8150099
-
Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome.Life Sci. 2019 Nov 1;236:116940. doi: 10.1016/j.lfs.2019.116940. Epub 2019 Oct 8. Life Sci. 2019. PMID: 31604107 Review.
-
Polycystic Ovary Syndrome.Obstet Gynecol. 2018 Aug;132(2):321-336. doi: 10.1097/AOG.0000000000002698. Obstet Gynecol. 2018. PMID: 29995717 Review.
Cited by
-
Synergistic Amelioration of Letrozole-induced Polycystic Ovary Syndrome in Rats: A Therapeutic Approach with Apple Cider Vinegar and Metformin Combination.Reprod Sci. 2024 May 22. doi: 10.1007/s43032-024-01545-4. Online ahead of print. Reprod Sci. 2024. PMID: 38777948
-
Correlation between anti-mullerian hormone with insulin resistance in polycystic ovarian syndrome: a systematic review and meta-analysis.J Ovarian Res. 2024 May 18;17(1):106. doi: 10.1186/s13048-024-01436-x. J Ovarian Res. 2024. PMID: 38762718 Free PMC article.
-
Alternative treatment of polycystic ovary syndrome: pre-clinical and clinical basis for using plant-based drugs.Front Endocrinol (Lausanne). 2024 Jan 11;14:1294406. doi: 10.3389/fendo.2023.1294406. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38725974 Free PMC article. Review.
-
Food Cravings and Obesity in Women with Polycystic Ovary Syndrome: Pathophysiological and Therapeutic Considerations.Nutrients. 2024 Apr 3;16(7):1049. doi: 10.3390/nu16071049. Nutrients. 2024. PMID: 38613082 Free PMC article. Review.
-
Mechanism of elevated LH/FSH ratio in lean PCOS revisited: a path analysis.Sci Rep. 2024 Apr 8;14(1):8229. doi: 10.1038/s41598-024-58064-0. Sci Rep. 2024. PMID: 38589425 Free PMC article.
References
-
- Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertility and Sterility. 2012;97(1):28.e25–38.e25. - PubMed
-
- Boyle J, Teede HJ. Polycystic ovary syndrome—an update. Australian Family Physician. 2012;41(10):752–756. - PubMed
-
- Lane DE. Polycystic ovary syndrome and its differential diagnosis. Obstetrical and Gynecological Survey. 2006;61(2):125–135. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources